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Summary We studied 1771 patients treated for a thyroid cancer in two institutions. None of these patients had been treated with external
radiotherapy and 1497 had received 1311. The average 1311 cumulative activity administered was 7.2 GBq, and the estimated average dose was
0.34 Sv to the bone marrow and 0.80. Sv to the whole body. After a mean follow-up of 10 years, no case of leukaemia was observed,
compared with 2.5 expected according to the coefficients derived from Japanese atomic bomb survivors (P = 0.1). A total of 80 patients
developed a solid second malignant neoplasm (SMN), among whom 13 developed a colorectal cancer. The risk of colorectal cancer was
found to be related to the total activity of 1311 administered 5 years or more before its diagnosis (excess relative risk = 0.5 per GBq, P= 0,02).
These findings were probably caused by the accumulation of 1311 in the colon lumen. Hence, in the absence of laxative treatment, the dose to
the colon as a result of 1311 administered forthe treatment of thyroid cancer could be higher than expected from calculation of the International
Commission on Radiological Protection (ICRP). When digestive tract cancers were excluded, the overall excess relative risk of second cancer
per estimated effective sievert received to the whole body was -0.2 (P = 0.6).
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On account of the small population dose involved, published
studies (IARC, 1994) of nuclear industry workers do not have
sufficient power to make reliable comparisons with the risks esti-
mated from the Japanese atomic bomb survivors (UNSCEAR,
1994). Hence, studies of adult populations undergoing protracted
exposure to radiation for medical reasons are still necessary.
For this purpose, '3'I is a suitable model, because its physical half-
life is 8 days. The risks of solid tumours and leukaemia after
administration of '3'I have been studied in several cohorts ofadults
(Hall et al 1991, 1992; Dottorini et al, 1995); nevertheless, the
statistical power of these studies is still insufficient to derive
precise coefficients.
Another reason for studying the carcinogenic effects of '3'I is
the fact that considerable amounts of various radioisotopes of
iodine, including '3'I, were released in the atmosphere during the
Chernobyl accident. A substantial increase in thyroid cancer inci-
dence has been observed in children living in the most heavily
contaminated areas at the time of the accident (Stsjazhko et al.
1995), but no increased incidence ofother malignancies, including
leukaemia, has been reported so far. More data are thus needed to
predict future risks in populations that have been contaminated.
We report the results of a study of 1771 patients treated for a
thyroid cancer, of whom 651 had received 1311 for diagnosis, and
846 for therapy.
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PATIENTS AND METHODS
Patients
From 1989 to 1995, all 2479 patients treated for a differentiated
thyroid cancer in the two participating institutions between 1950
and December 1989 were studied.The same protocols oftreatment
and follow-up were used in both centres.
Among the 2479 patients, 173 patients were excluded because
they had died or were lost to follow-up during the first two years
after the diagnosis of thyroid cancer; 449 patients because they
had received external beam radiotherapy, known to be carcino-
genic (among whom three developed a leukaemia) and 86 patients
because they had had another cancer before thyroid cancer or
during the first two years offollow-up.
The remaining 1771 patients were included in the present
analysis, of whom 21% were male (Table 1). The mean age at the
first treatment of thyroid cancer was 40 years (range 5-89 years).
The histology of the thyroid tumour was papillary in 72% of the
patients, well-differentiated follicular in 13% and poorly differen-
tiated follicular in 12%. The thyroid tumour was clinically occult
in 8% ofthe patients, was associated with a goitre in 23% and with
Graves' disease in 2%.
All patients except 11 underwent thyroid surgery: 64% a total
thyroidectomy, 34% a lobo-isthmusectomy, 1% an isthmusectomy
and 1% a tumorectomy. Sixty-nine per cent of the patients had
lymph node dissection. Post-operatively, a standard ablative dose
of 3.7 GBq (100 mCi) was given to patients with poor prognostic
indicators or with persistence of neoplastic tissue. After the initial
treatment, all patients were followed by two of us (MS and MJD)
at a yearly interval for 10 years and then every 2 years. A total
body scan with a diagnostic activity of 13'I ranging from 19 to 190
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Table 1 General characteristics of the present cohort and of the other two major cohort studies concerning the effect of 1311 administered for thyroid cancer
Present Swedish Italian
cohort cohort cohort
Patients
Number 1771 1955 931
Treatment period 1950-1989 1950-1975 1960-1990
Males (%) 21 25 25
Mean age at thyroid cancer diagnosis (years) 40 48 42
Total thyroidectomy (%) 64 42 61
Treatments
External beam radiotherapy (%) 0 37 6
No 1311 274 (16%)
Only diagnostic 1311 administrations 651 (37%) 1121 (57%) 201 (22%)
Mean cumulative 1311 activity in GBq (range) 0.6 (0.002-10.9) ? ?
Therapeutic administration of 1311 846 (48%) 834 (43%) 730 (78%)
Mean cumulative 1311 activity in GBq (range) 7.2 (3.8-57.6) 4.8 (0.48-50.3) 4.6 (1.9-44.4)
Mean 24-h uptake 13% 13% ?
Mean dose to bone marrow in Sv (range)a 0.34 (0.13-2.8) 0.25(0.03-2.2) ?
Follow-up
Mean duration in years 10 16 8
End of follow-up 1992 1984 1993
Second leukaemias 0 8 0
Second solid malignant neoplasms 80 213 31
aAccording to ICRP tables.
MBq (0.5-5 mCi) was performed each year for the first 2 years of
follow-up and then every 5 years.
The histological diagnosis of the second primary malignancies
was reviewed for90% ofthe cases. Cause ofdeath was obtained in
138 ofthe 143 patients who died during the study.
Dosimetry
For each diagnostic or therapeutic administration of 'l'I, we
recorded the day of administration and the activity administered;
the sites, the percentage ofuptake in the neck, lungs and bones, as
shown by '31I total body scan (TBS), and the number ofdays from
'3'I to TBS were also recorded.
A total of274 patients did not receive any 1311,501 wereexposed
to one or several diagnostic activities of 131J equal or less than 0.19
GBq. These patients received a cumulative activity ranging from
0.002 to 0.79 GBq (mean = 0.15 GBq). A total of292 patients were
also exposed to activities of '3'I higher than 0.19 GBq for diag-
nostic purposes, but were not given therapeutic activities of 3.7
GBq or more. They received a cumulative activity from 0.20 to
10.9 GBq (mean = 1.2 GBq). The 846 other patients received at
least one therapeutic activity of 3.7 GBq or higher, leading to a
cumulative activity from 3.8 to 57.6 GBq (mean = 7.2 GBq).
Quantitative uptake in lung and bone as well as the day of
measurement were recorded for 5532 (93%) of the 5948 adminis-
trations < 0.19 GBq, and for 1385 (85%) of the 1629 administra-
tions > 0.19 GBq.
After the administration of0.19 GBq of 131J or less, the average
total uptake was 22% at 24 h (n = 395 administrations), 18% at 2
days (n = 925), 7% at 3 days (n = 4076), 3% at 4 days (n = 41) and
5% at 5 days (n = 509). After the administration of more than
0.19 GBq of 131I, the average total uptake was 13% at 24 h
(n = 14 administrations), 13% at 2 days (n = 15), 5% at 3 days
(n = 244), 3% at 4 days (n = 306), 8% at 5 days (n = 1027) and 5%
at 6 days (n = 23).
In the absence of any other simple method, we added the neck,
bone and lung uptake values and entered this 'total' uptake under
neck uptake in the International Commission on Radiological
Protection (ICRP) tables (ICRP, 1988), in order to estimate the
dose delivered to various organs,assuming abiological half-life of
4 days for 'III (Harbert et al, 1987). If not available (n = 416),
uptake after diagnostic administration was estimated as a linear
function ofthe variables shown toplay arole in ourcohort: admin-
istered activity, age at diagnosis (>/< 40 years), presence of a
goitre (yes/no) and extent ofthyroid surgery (total/not total). In the
same way, if not available, uptake after a therapeutic administra-
tion (n = 244) was estimated as a linear function of age at diag-
nosis (>/< 40 years), extent ofthyroid surgery (total/not total) and
order of the therapeutic administration (first therapeutic adminis-
tration or subsequent).
The mean whole body effective dose equivalent was estimated
using ICRP tables (ICRP, 1988), assuming a null dose to the
thyroid. According to these tables, the 1497 patients exposed to
'III received a mean whole body equivalent dose equal to 0.49 Sv,
a mean dose to active bone marrow of0.21 Sv and a mean dose to
the breast of0.18 Sv. In the 846 patients who had received at least
one therapeutic activity of3.7 GBq or more, these doses were 0.80
Sv, 0.34 Sv and 0.29 Sv respectively. The difference between the
dose to the whole body and to the active bone marrow resulted
from the high doses to organs in which there is an accumulation of
'13I and which were taken into account in the estimation of the
whole body effective dose equivalent: bladder, digestive tract
organs and kidney. In our series, a therapeutic administration of
3.7 GBq delivered a mean estimated dose to active bone marrow
of0.16 Sv, and a mean effective dose to the whole body of0.39 Sv.
ICRP tables were designed for intravenous administrations of
radioiodine and may be adapted to oral administration of radioio-
dine by multiplying by 1.3 the estimations of the dose to the
stomach (ICRP, 1988). In these tables, the radiation dose to the
upper and lower part of the colon does not vary significantly with
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Figure 1 Example of a total body scan performed 4 days after a therapeutic
administration of 3.7 GBq of 1311. Uptakes are expressed as percentages of
the administered activity of 1311. No laxative treatment was given to this
patient. S, stomach; I, intestine; B, bladder
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uptake. In euthyroid subjects, the accumulation of radioiodine in
colon is low or absent. In contrast, thyroid cancer patients are
hypothyroid at the time of the administration of '3'I, and consider-
able activities (from 1% to 3% at 4 days) were observed in the
colon lumen, due to a decrease in bowel movements. Figure 1
presents a total body scan performed 4 days after the administra-
tion of 3.7 GBq of 1311. As a consequence, laxative treatment has
been given after each therapeutic administration since 1985.
Because of this inconsistency with ICRP tables, and as, to our
knowledge, no estimation ofthe dose to colon after 1311 administra-
tion to thyroid cancer patients has been published (Smith et al,
1984), we did not perform an estimation of doses to organs of the
digestive tract, and we performed the analysis of the risk of
colorectal cancer as a function of the cumulative administered
activity of '3'I.
Statistical procedure
The end point of the study was at 1 January 1992. Hence, patients
were considered at risk of second cancer during the period begin-
ning 2 years after the diagnosis oftheir thyroid cancer and ending
at the date of the end of follow-up. This date was defined as the
first of the four following events: (1) 1st January 1992;(2) occur-
rence of a second cancer;(3) death ofthe patient;(4) last visit ofthe
patient to one our institutions. Patients who were not seen on 1
January 1992 or later, and who were alive and without second
primary at their last visit were defined as lost to follow-up.
Since there is no national cancer registry in France and since
local registries did not cover the study period, the main analysis
used internal comparisons. The risk of second malignant neoplasm
(SMN) was modelled, using internal analysis, as a function '3'I (in
GBq) administered 5 years or more before its occurrence, as contin-
uous covariates. This period oftime of 5 years was chosen because
radiation delivered less than 5 years before the development of a
solid cancer is very unlikely to have contributed to it. This method
enabled us to control for the variations of the cumulative adminis-
tered activities within two groups, i.e. in those who received only
diagnostic '3'I and those who were also treated with '3'I. As
Figure 2 Cumulative incidence of solid second malignant neoplasms and
95% Cl
compared with external analysis, this method also enabled us to
control for a hypothetical predisposition of thyroid cancer patients
to develop another cancer subsequently, regardless of treatment.
The number of cancers was assumed to follow a Poisson distrib-
ution (Breslow et al, 1987). The excess relative risk (ERR) of
cancer for a given treatment centre, calendar period of 10 years,
sex and attained age was modelled as a linear or/and quadratic
function ofcumulative activity of '3'I administered 5 years or more
before. Modifiers of the effect of '3'I activity were tested. The
following models were used:
(1) ERR = 0
(2) ERR = (yl 2 +yb2) exp (a, a, + a2 a2)
as well as intermediate models obtained by selecting any of the
following constraints: y2 = a, = a2 = 0, ,y = a, = a2 = 0, a2 = 0 or
a, =0,
where a = 0 for male, 1 for female;
a2 = I for a patient over age 40 at the time of thyroid cancer treat-
ment, 0 otherwise; b = cumulative activity of '3'I, or estimated
dose to organs of interest according to the analysis, delivered 5
years or more before.
The significance of the parameters was tested by comparing the
deviances of nested models. The analysis was done using AMFIT
software (Preston et al, 1993).
We used external comparisons for leukaemia, because no varia-
tion in leukaemia incidence has been observed in Europe over
more than 30 years (Coleman et al, 1993; IARC, 1992). We there-
fore estimated the expected number of leukaemias in our cohort,
using incidence rates of leukaemia by age and sex estimated for
France for the period 1978-1982 (Benhamou et al, 1990).
RESULTS
Of the 1771 patients included in the study, 143 died and 220
(12%) were lost to follow-up. The mean follow-up period after the
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Table 2 Characteristics of the 80 second malignant neoplasms (SMNs) observed in the 1771 patients
Cancer site (ICD9 code) Patients Years since Age at diagnosis Cumulative 1311
(n) thyroid cancer of SMN activity before the
(years) SMN (GBq)
Mean Min-max Mean Min-max Mean Min-max
Oral cavity (140-149) 3 9 4-14 49 47-51 0.1 0-0.2
Salivary gland (142) 1 9 - 50 - 0.2 -
Digestive tract (150-159) 16 13 2-29 62 34-86 5.9 0.06-22.9
Colon (153) 10 13 3-31 59 34-73 3.6 0.09-11.7
Rectum (154) 3 19 8-29 67 57-86 12.9 0.09-22.9
Respiratory organ (160-163) 4 7 2-11 62 49-70 4.6 0-13.7
Bone(170) 1 8 - 26 - 6.4 -
Skin melanoma (172) 4 10 7-19 50 37-61 0.2 0.04-0.4
Other skin tumour (173) 9 14 5-32 61 45-80 2.7 0-9.8
Breast cancer (1 74-175) 21 12 2-37 51 30-68 0.9 0-3.9
Female genital organ (179-184) 7 8 2-13 63 51-82 2.4 0-8.0
Male genital organ (185-187) 1 18 - 86 - 0.1 -
Kidney (189) 2 16 16-16 66 54-77 0.2 0.06-0.4
Nervous system (191-192) 2 8 5-11 56 52-59 5.9 4.0-7.8
Endocrine gland (194) 0 - - - - -
Lymphoma (200-202) 4 4 2-8 52 21-65 2.4 0.5-3.9
Myeloma (203) 2 9 7-11 61 57-64 7.7 4.0-11.4
Others 4 9 2-22 51 43-62 3.0 0-7.9
Total 80 11 2-37 57 21-86 2.9 0-22.9
Table 3 Distribution of the 60 second cancers, which occurred more than 5
years after first cancer diagnosis, according to the type of 1311 administrations
2 5 years after treatment
Cancer site (ICD9 code) 1311 administration
No 1311 Only At least one
(n = 162) diagnostic therapeutic
activities of activity of
1311 3.7 GBq 1311.3.7
(n= 520) GBq
(n = 593)
Oral cavity (140-149) 1 1
Digestive tract (150-159) 5 7
Respiratory organ (160-163) 1 2
Bone (170) 1
Skin melanoma (172) 4
Other skin tumour (173) 1 3 5
Breast cancer (174-175) 4 7 3
Female genital organ (179-184) 1 3 1
Male genital organ (185-187) 1
Kidney (189) 2
Nervous system (191-192) 1
Lymphoma (200-202) 2
Myeloma (203) 2
Others 1 1
Total 9 27 24
diagnosis of thyroid cancer was 10 years (range 2-37 years).
When the first two years of follow-up were excluded, a total of
14 615 person-years at risk were observed.
Between 2 to 37 years after the diagnosis of thyroid cancer, 80
patients developed a SMN (Figure 2 and Table 2). Of the 1275
patients followed at least 5 years, 60 developed a SMN 5 years or
more after first cancer diagnosis (table 3). No difference in the
frequency of SMN according to sex, histology or to the presence
of a goitre was observed.
Table 4 Relative risk (RR) of colorectal carcinoma as a function of the
cumulative activity of 1311 administered 5 years or more before the diagnosis
of colorectal cancer
Cumulative activity of Patients Colorectal carcinomas
1311 (GBq) administered (n)
5 years or more before
n Relative risk 90%CI
0-0.19 1051 6 1.0a
> 0.19-3.7 184 1 1.4 (0.2-6.8)
> 3.7-7.5 380 4 4.0 (1.3-12.2)
> 7.5 156 2 4.9 (1.2-18.5)
aReference category. Poisson's regression analysis was stratified on sex,
treatment centre, calendar period and attained age.
Among the 155 patients aged less than 20 years atthe diagnosis of
thyroid cancer, 84 received therapeutic activities of 13'I. Five SMNs
occurred, two breast carcinomas, one bone sarcoma, one basocel-
lular skin carcinoma and one non-Hodgkin's lymphoma. Only one
ofthese SMNs occurred after a therapeutic administration of 13'l.
Leukaemias
No case of leukaemia was observed among the 1497 patients
exposed to I3'l, compared with 1.28 cases expected from French
general population data (Benhamou et al, 1990). Assuming a mean
total dose to the bone marrow of0.21 Sv and using an ERR per Sv
for all leukaemia types of 4.4 obtained from the study of adult
atomic bomb survivors (UNSCEAR, 1994), 2.5 leukaemias were
expected, compared with 0 observed (P = 0.1).
Digestive tract cancers
Among the whole cohort, 16 patients developed a cancer of the
digestive system, of which 13 were colorectal. Among the 1275
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patients followed 5 years or more, 12 developed a digestive system
cancer, namely one abdominal lefomyosarcoma, eight colon and
three rectum cancers. The ERR for cancer of the digestive system
was 0.34 (90%Cl, 0.05-1.09, P = 0.02) per GBq of '3'I adminis-
tered 5 years or more before its discovery. When restricting the
analysis to the 11 colorectal cancers, the risk was 0.47 (90%Cl,
0.1-1.6, P = 0.02) per GBq administered 5 years or more before
the discovery of the colorectal cancer. No significant quadratic
term was found. Table 4 illustrates this result, presenting, for the
whole cohort, the relative risk of colorectal cancer according to
various categories of activity administered 5 years or more before
the discovery of colorectal cancer.
All solid cancers
For the whole cohort, the overall ERR for all solid cancers was
0.38 (90%Cl - 0.22 to 1.2, P = 0.3) per estimated effective Sv to
the whole body received 5 years or more before the discovery of
the SMN. The ERR for all cancers, excluding digestive tract
cancers, was equal to -0.16 (90%Cl - 0.35 to 0.22, P = 0.6) and
was not significantly modified by sex or by age at the diagnosis of
thyroid cancer.
DISCUSSION
The three main results of this study of 1771 patients treated with
13l1 for a thyroid cancer, who were followed for 10 years on
average, are: (1) a strong relationship between the cumulative
administered activity of '31I and the risk of colorectal cancer,
which suggests that the radiation dose to the colon could be higher
in thyroid cancer patients than expected from ICRP tables; (2) the
absence of leukaemia occurrence during the follow-up; and (3) the
absence of an excess risk of SMN when excluding colorectal
cancers.
All patients were followed by two of us, with a visit at our insti-
tutions each year for 10 years and every 2 years thereafter.
Consequently, it is very unlikely that a second cancer occurring in
a patient not lost to follow-up could have been missed. We think
that the 12% of patients lost to follow-up before 1992 did not
introduce any bias in our results because this was not linked to the
patients' health status, but rather to the routine long-term follow-
up programme.
The risk of secondary cancer after thyroid cancer has been
studied in two other large cohorts (Table 1). The Swedish study
involved 1955 2-year survivors followed for 17 years on average,
of whom 834 were treated with '31I (Hall et al, 1991). This cohort
was included in a large cohort of46 988 Swedish patients who had
received 13'I for various medical reasons (Hall et al, 1992). The
Italian study included 931 three-year survivors followed for
8 years on average, of whom 730 were treated with 131I (Dottorini
et al, 1995).
Unlike these authors, we excluded all patients who had received
external radiotherapy whatever the site of irradiation, since
external beam radiotherapy is known to be carcinogenic (Boice et
al, 1987). A complete adjustment for external beam radiotherapy
would require a model allowing for the heterogeneity of dose
distribution (Boice et al, 1987), rather than for the presence or
absence of external beam radiotherapy.
In contrast with the other two studies, we did not use cancer
incidence registry data as a reference, except for leukaemia (Hall
et al, 1991; Dottorini et al, 1995). This makes our analysis less
powerful, but also less sensitive to a possible excess of second
cancers owing to a hypothetical genetic mechanism associated
with thyroid cancer rather than with '3'I. Also in contrast with
other authors, we did not compare directly the incidence of cancers
in the group of patients who received at least one therapeutic
activity of '3'I to that observed in the group of patients who
received no or only diagnostic activities of 'I'I. We made an
internal analysis with the actual activities of I3'l, expressed in
GBq, as a continuous covariate in a regression analysis. This
choice was made in order to control for the variation of the admin-
istered activities within the two groups. In fact, because of the
large difference in values between the diagnostic and the thera-
peutic activities of '3'I, our method is not very different to that
which takes as a reference group the group of patients who
received no or only diagnostic activities of '3'I. It is, nevertheless,
more accurate because, in our series, each diagnostic activity
ranged from 0.001 to 0.19 GBq, and some of these patients had
received a cumulative activity of 3'I higher than 0.5 GBq,
although they were exposed only to multiple diagnostic activities.
Moreover, patients who received therapeutic activities of 131I did
not constitute a homogeneous group, some patients having
received 15 GBq or more. For all these reasons, an analysis with
'3'I as a continuous variable appeared to be more appropriate.
We did not observe any case of leukaemia among the 1434
patients exposed to 1311, whereas 2.4 cases were expected from
coefficients derived from atomic bomb survivors (P = 0.1). This is
consistent with the absence of leukaemia in the Italian study
(Dottorini et al, 1995), in which about 1.09 leukaemias were
expected among the 730 patients who had been exposed to '3'I,
assuming a mean dose to bone marrow of 0.25 Sv for these
patients. A non-significant relative risk of leukaemia of about
2 was reported in the Swedish study (Hall et al, 1991, 1992).
However, 37% of the Swedish patients had also received external
radiotherapy. Similarly, three cases of leukaemia were observed
among the 449 patients who were excluded from our analysis
because they had received external beam radiotherapy, compared
with 0.62 expected (P = 0.03). These patients had also received
high cumulative doses of '3'I (Schlumberger et al, 1996). Hence,
more investigations are necessary to assess the respective role of
high activities of 131I and ofexternal beam radiotherapy (Brown et
al, 1984; Edmonds et al, 1986; Brinker et al, 1987). This result is
strengthened by the fact that the dose from3'1I delivered to bone
marrow could be higher in thyroid cancer patients than estimated
in ICRP tables for euthyroid subjects (ICRP, 1988), because the
hypothyroid status of these patients decreases the renal clearance
of 1311, thus increasing the whole body retention of 1311 and the
mean whole body radiation dose.
The overall ERR for solid tumours per estimated effective Sv
received to the whole body 5 years or more before was 0.38 (90%
Cl -0.22 to 1.2) in the whole cohort. This value is similarto thatof
0.4 obtained in the Swedish study (Hall et al, 1991) and to the
value of0.6 (90% Cl 0.5-0.7) estimated for the incidence of solid
cancers after exposure in adulthood of the atomic bomb survivors
(UNSCEAR, 1994). In the Italian study, no dose estimation was
published, but the relative risk of 1.2 for exposed patients would
probably lead to an ERR per Sv of about 0.4 (Dottorini et al,
1995). Nevertheless, the length of the follow-up in our cohort (10
years on average) is short and needs to be increased in order to
evaluate the risk ofsecond solid cancer with more accuracy.
After administration of 131I for thyroid cancer, organs of the
digestive tract, the salivary glands and the bladder are particularly
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exposed, owing to local accumulation of I3'l. Our site-by-site study
detected an increased risk only for colorectal cancer, which has not
been reported in previous studies. The Swedish study showed a
non-significant increased risk for stomach cancer, but did not
provide detailed data for other organs of the digestive tract. In the
Italian study, a non-significant excess was found for colorectal
carcinoma, but not for stomach cancer (Dottorini et al, 1995).
We found no excess of salivary gland tumours, unlike the two
other studies in which this excess was based on only three cases
(Hall et al, 1991; Dottorini et al, 1995). The Swedish study showed
a non-significant increased risk of bladder cancer (Hall et al,
1991), which is in accordance with the findings of a British study
(Edmonds et al, 1986), but this was not found in our study nor in
the Italian study (Dottorini et al, 1995).
A possible explanation for the difference of results concerning
the colorectal carcinomas could be the role of co-carcinogens,
such as dietary factors. Of note is that no case of familial adeno-
matous colon carcinoma was recorded in our cohort.
In any case, our findings concerning cancer ofthe digestive tract
cannot be applied to the general population or to thyrotoxic
patients treated with '3'I, since the accumulation of I3'l is low or
absent in the colon lumen of euthyroid or thyrotoxic patients.
Moreover, the excess of SMN found in our series was observed in
patients exposed to several GBq of '3'I, quantities which are much
larger than those involved in the contamination resulting from the
Chernobyl accident (Stsjazhko et al, 1995).
Our results confirm the paucity ofevidence for an increased risk
of cancer of the breast, kidney or female genital organs in thyroid
cancer patients treated with I3'I. As found in the Swedish but not in
the Italian study (Hall et al, 1991; Dottorini et al, 1995), the risk of
breast cancer was lower among females who had received I3'I than
among females who had not. We found an excess ofmyeloma, but
only two cases were observed.
As only 155 patients were under 20 years at diagnosis ofthyroid
cancer, our study is not informative concerning the carcinogenic
effects of '3'I exposure in childhood, which is a major concern
since the Chernobyl accident.
In conclusion, this study suggests that, in the absence oflaxative
treatment, the dose to the colon as a result of the activity of '3'I
could be higher than expected from the calculation ofthe ICRP. In
our series, except for colorectal carcinoma, no evidence was found
for an increased overall risk of cancer or leukaemia owing to ther-
apeutic or diagnostic administration of I3II.
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